Silexion Therapeutics says holders exercise warrants for 3,216,928 shares at $0.2603 each
SLXN•Silexion Therapeutics entered agreements for immediate exercise of Series E warrants covering 3,216,928 shares at $0.2603 each, expecting gross proceeds of $837,366.36. The company will issue Series F and G warrants and cut the exercise price on other outstanding Series E warrants to $0.2603.
1. Warrant exercise terms
Silexion Therapeutics said holders agreed to immediately exercise Series E warrants for 3,216,928 ordinary shares at $0.2603 each, with closing expected around Sept. 29, 2026. The company expects gross proceeds of $837,366.36. In exchange, it will issue unregistered Series F warrants for 3,216,928 shares, expiring five years after specified effectiveness dates, and Series G warrants for the same number of shares, expiring 24 months after those triggers. Silexion also cut the exercise price to $0.2603 for outstanding Series E warrants covering 3,846,161 ordinary shares.
